Medical

3D Bioprinting for Drug Discovery and Development

3D bioprinting is a relatively new technology that has the potential to revolutionize drug discovery and development. Here are some ways 3D bioprinting can help in this field: 1) Generating realistic in vitro models: 3D bioprinting can create three-dimensional tissue structures that closely mimic the in vivo environment. These structures can be used to test the efficacy and toxicity of drugs in a more realistic setting than traditional two-dimensional cell culture methods. This can help researchers identify promising drug candidates earlier in the drug development process, which can save time and resources. 2) Personalized medicine: 3D bioprinting can be used to create patient-specific tissues or organs for drug testing. This can help identify drugs that are effective for a particular patient population, as well as identify potential adverse effects that may not be detected in traditional preclinical testing. 3) High-throughput screening: 3D bioprinting can enable the creation of large numbers of complex tissue models in a relatively short amount of time. This can allow for high-throughput screening of potential drug candidates, which can speed up the drug discovery process and reduce costs. 4) Target identification: 3D bioprinting can help researchers identify new drug targets by enabling the creation of more complex tissue structures that better mimic the in vivo environment. This can provide researchers with a more complete understanding of disease biology and help identify new therapeutic targets. 5) Overall, 3D bioprinting has the potential to improve the drug discovery and development process by enabling the creation of more realistic in vitro models, accelerating the drug discovery process, and improving patient outcomes through personalized medicine. In this highly anticipated event, we invite critical stakeholders in the 3D bioprinting drug development ecosystem to update the community on where we are in terms of technologies and commercialization of the technologies.

Speakers:

Andrew Lee

Andrew Lee is a co-founder at FluidForm, a 3D biofabrication company looking to change the way we think about tissue engineering and regenerative medicine. He currently is the Product Manager for the Cardiac Group at FluidForm. He received his Ph.D. in Biomedical Engineering at Carnegie Mellon University where his focus on muscle tissue engineering leveraged biofabrication to create skeletal and cardiac tissue models with complex tissues architecture as well as physiologically relevant contractile functions. This work resulted in a publication in the journal Science and is now utilized as the platform technology for FluidForm as it builds out a portfolio of tissues for research, repair, and replacement.

Kevin Vos

Kevin is the Director of Preclinical R&D at VoxCell BioInnovation. He acquired his Bachelor’s of Science from the University of Victoria in Biochemistry. He then completed his Ph. D. also from the University of Victoria in physical chemistry studying the photo-physical characterization of supramolecular complexes. After his Ph.D., Kevin completed a post-doctoral fellowship at the University of Calgary working with the World Health Organization studying the decontamination and reuse of PPE during the SARS-CoV-2 pandemic. Kevin then joined VoxCell in December 2021, as a tissue engineering scientist where he now leads the development of VoxCell’s tissue models.

Orquidea (Orchid) Garcia, PhD, MS

As a Johnson & Johnson Fellow and Lead for 3D Bioprinting and Tissue Regen Technologies, Orquidea (Orchid) Garcia is the technical lead for 3D bioprinting, and related tissue regen technology development. She is responsible for evaluation and execution of technical strategies and new technology integration to develop a new class of next-generation healthcare solutions. Orchid works closely with internal business partners, as well as technology, academia and government partners to develop J&J’s bioprinting capabilities.    

Orchid has extensive experience identifying novel technologies through scientific discovery and translating them into patentable, marketable technologies both in industry and academia. Having served as the scientific subject matter expert on numerous initiatives, she brings a keen understanding of world-wide technical, scientific, regulatory and policy issues that face the business. Orchid has also held various positions within J&J and in industry in Clinical Affairs, Medical Affairs and Regulatory Affairs. 

Isabella Bondesson

isabella bondesson

Isabella Bondesson is a Field Application Scientist at CELLINK, the global leading bioprinting company. Isabella has a BioTech Engineering degree from Chalmers Institute of Technology, and she joined CELLINK in 2018 as part of the R&D team to develop novel methods in tissue model printing. During her time at CELLINK Isabella has acquired expertise in multiple areas of bioprinting and is today leading the EMEA Application team who work with consulting, educating, and supporting customer needs within various aspect of 3D Bioprinting. As the leading 3D bioprinting company, CELLINK is committed to providing the most advanced 3D bioprinting products, services and technologies needed to understand and master biology. CELLINK develops technologies that democratize 3D bioprinting – providing the leading researchers in the world the tools they need to create the future of health.

Moderator:

Dr. Jenny Chen

jenny chen

Dr. Jenny Chen is trained as a neuroradiologist, and founder/CEO of 3DHEALS. Her main interests include next-generation education, 3D printing in the healthcare sector, automated biology, and artificial intelligence. She is an angel investor who invests in Pitch3D companies.

3D Printing and Bioprinting Bones

3D printing and bioprinting to regenerate bone both are promising for the regeneration of bone tissue. It uses 3D printing to create acellular scaffolds or 3D bioprinting bio-inks that contain living cells and growth factors to promote bone growth. This technology has the potential to create exact replicas of damaged bone, which could then be implanted in the body to help regenerate lost tissue. The process begins with scanning the bone defect to create a 3D model of the desired bone structure. Then, biomaterials or bio-ink containing stem cells and growth factors are printed in the desired structure based on the 3D models. The scaffold acts as a supportive structure for the cells, which are then allowed to grow in the desired shape. Once the cells have grown and matured, they can then be implanted into the patient’s body. This technology has been successfully used to regenerate bone in animals and is now being tested in human clinical trials. Some of the forerunners in the field include Osteopore (Singapore), Ossiform(Denmark, previously known as Particle 3D), DimensionInx(U.S., Chicago), and Cerhum(Belgium). In this upcoming virtual event, we invite all stakeholders with different backgrounds to learn and participate focusing on how we can use 3D printing to regenerate bone tissues.

Speakers:

Raphael Lichtnecker

Raphael Lichtnecker

I got my Master´s degree in Pharmaceutical Bioprocess Engineering at Technical University Munich. Afterwards I started as Business Development Manager at ViscoTec where I am responsible for the technology transfer of the progressive cavity pump to the bioprinting sector. I´m in this position for almost five years now.

Elisabeth Cobraiville

Elisabeth is a biomedical engineer specialized in biomaterials. She also holds a university certificate in Quality, Regulatory and Clinical Affairs of medical devices. Prior to joining CERHUM, she worked in a CRO and managed preclinical and clinical trials. She joined CERHUM almost 4 years ago and she is in charge of the products technical file, animal studies and clinical trials.

Daniel Kelly

Prof Daniel Kelly leads a multidisciplinary musculoskeletal tissue engineering group based in the Trinity Centre for Biomedical Engineering. The goal of his lab is to understand how environmental factors regulate the fate of adult progenitor cells and the tissues they produce. This research underpins a more translational programme aimed at developing novel tissue engineering and 3D bioprinting strategies to regenerate damaged and diseased musculoskeletal tissues. To date he has published over 200 articles in peer-reviewed journals. He is the recipient of four European Research Council awards (Starter grant 2010; Consolidator grant 2015; Proof of Concept grant 2017; Advanced grant 2021).

Denys Gurak

Denys Gurak is an experienced C-level manager and serial entrepreneur. He is a CEO and Co-Founder at A.D.A.M., a 3D bioprinting company with a primary focus on 3D-printed bones. Denys’s ultimate vision is to build an on-demand personalized tissue manufacturing platform that would be a one-stop shop for transplanted tissues and organs; and, hence, to cut barriers to medical treatment for millions. Denys’s passion for biotech can be traced back to 2010, when he was leading the international relations and certification, along with EU legislation adaptation at the Ukrainian medicinal products regulatory authority (official position – director of the «GMP/GDP Center» of the State Administration of Ukraine on Medicinal Products (SAUMP). In 2014 Denys joined the Ukrainian Defense Industry (a state defense conglomerate) in 2014 as the Deputy Director-General for foreign economic activity. During his time at the company, he managed the export-import operations that amounted to USD 1 billion yearly turnover. Furthermore, Denys represented Ukraine as the Head of Ukraine’s delegation to the NATO Industrial Advisory Group (NIAG), and led the industry transformation initiatives, including innovations development and technology JVs, as well international relations. Denys is a Venture Partner at ff Venture Capital a high-performing early stage venture firm based in NYC and Warsaw, Poland, focusing on disruptive IT, biotechnology, aerospace and security projects in CEE region.

Dan Rogozea

Dan Rogozea started working in the bioprinting field with the mission to produce the smallest bones in the human body, the ossicles. This project started in 2018 and initiated his work in the bioprinting field. In collaboration with Dr. Moldovan at the Roudebush VA Medical Center Bioprinting Core, he has continued to work in multiple projects in different fields ranging from cardiovascular to dental bioprinting projects. As an expert in the field Dan Rogozea continues to work in research and for well -known bioprinting companies.

Moderator:

Dr. Jenny Chen

jenny chen

Dr. Jenny Chen is trained as a neuroradiologist, and founder/CEO of 3DHEALS. Her main interests include next-generation education, 3D printing in the healthcare sector, automated biology, and artificial intelligence. She is an angel investor who invests in Pitch3D companies.

3D Printing for Orthopedic Care

How useful is 3D printing in healthcare? Beyond the Aligner and hearing aid examples, the field of orthopedic care is perhaps the earliest and biggest adopter of this emerging technology. 3D-printed orthopedic solutions can be used to create customized implants and prostheses that are a perfect fit for each patient. This not only results in a better fit and more comfortable device, but it also leads to potentially faster healing times and longer durability. 3D printing presurgical planning either using anatomical models or surgical guides is now routinely used in the operating room. In this upcoming webinar, we primarily focus on orthopedic surgical care from several different perspectives. In a future webinar in April, we will focus on 3D printing or bioprinting bone tissue using tissue engineering techniques. The commercialization and regulatory pathways for 3D-printed orthopedic implants are approaching maturity, with industry leaders like Stryker, JNJ, and more continuing to expand their 3D printing product and service portfolio. Naturally, this is an active area of innovations and entrepreneurial activities, and investments, since short-term favorable exit is more likely compared to other applications. 

Speaker:

David Jansen

David Jansen

David Jansen is the CEO of SAIL Fusion, a company that develops novel sacroiliac fusion devices for spine surgeons built on AO principles. With a background in leading innovation at DePuy Synthes and Globus Medical, David brings a track record of launching innovative new technologies. His team is composed of industry veterans and leading spine surgeons, all working towards major improvements for the treatment of SI joint dysfunction.

Ruben Wauthle

Ruben started his career at LayerWise in Belgium (now 3D Systems) in 2010 as Medical Application Engineer and obtained a PhD in Mechanical Engineering in 2014 from KU Leuven on the topic of selective laser melting of porous titanium and tantalum implants. In 2015, he joined FMI Instrumed in the Netherlands where he started and managed the additive manufacturing division. Ruben returned to 3D Systems in 2017 as a director within the healthcare business unit, and was responsible for all sales in Europe for contract manufacturing and metal printer sales. Ruben is since 2020 co-investor and CEO of Amnovis, a 3D printing contract manufacturing and engineering company.

Brett Carey

Dr. Brett Carey is CEO of Kalo Multispeciality Group based in Kona, Hawaii. His clinic exclusively uses 3D printed hand orthoses for all post operative patients. Kalo has also performed clinical trials with Spentys Orthopedics, trialing Ankle-foot-orthoses within adult patient populations. Additionally, Brett is an Adjunct Professor at Hawaii Pacific University which became the first University to offer additive manufacturing education to Doctor of Physical Therapy students. He serves as a Key Opinion Leader in Orthopedics for Desktop Health and believes that additive manufacturing will help meet overarching healthcare system goals of decreasing cost while bettering patient outcomes.

Frédéric Schuind

Prof Frédéric Schuind is an orthopedic surgeon and professor with a career spanning several decades. He has held numerous positions throughout his career, including the Head of the Department of Orthopaedics and Traumatology at Hôpital Erasme in Belgium and as a Full Professor at the Université libre de Bruxelles. Prof Schuind specialized in orthopedics and traumatology, with a focus on prosthetics. He has been an active member of multiple scientific societies, including the role of President for the Société Royale Belge de Chirurgie Osseuse et de Traumatologie and the Belgian Orthopaedic Trauma Association. Dr. Schuind’s contributions to the field extend beyond his academic pursuits; he has also organized international meetings, undertaken surgical and educational missions in developing countries, and served as a reviewer for various journals.

Moderator:

Dr. Jenny Chen

jenny chen

Dr. Jenny Chen is trained as a neuroradiologist, and founder/CEO of 3DHEALS. Her main interests include next-generation education, 3D printing in the healthcare sector, automated biology, and artificial intelligence. She is an angel investor who invests in Pitch3D companies.

Canadian Healthcare 3D Printing Ecosystem

With a unique and different healthcare system and challenges from its immediate neighbor, the United States, this virtual event invites influencers in the Canadian healthcare 3D printing and bioprinting ecosystem to share with us how they are innovating, thriving, and solving entrepreneurial problems.

Speakers:

Kelly Knights

Kelly Knights is the Chief Operating Officer at Victoria Hand Project, a Canadian charity that provides highly-engineered 3D printed prosthetic arms to amputees in-need, worldwide. Primarily, Kelly focuses on human factors testing and liaison of communication between clinicians, software developers, and engineers. Kelly leads VHP marketing, and assists with fundraising, volunteer coordination, grant-writing, R&D, and supporting VHP international partners. She graduated from the University of Victoria with a B.Eng in Biomedical Engineering, and has been involved with Victoria Hand Project since 2016, filling various roles. Her focus and specialty is cost-effective 3D solutions, scalable to remote and low-income areas, used to create creative healthcare solutions that serve those most in-need.

Mohamed Gamal

Dr. Gamal has spent over a decade working in the pharmaceutical industry as a community pharmacist, product specialist, and pharmaceutical trainer. In 2012, he earned a Master’s Degree in Stem Cells and Regeneration from the University of Bristol. He then obtained a PhD in Biomedical Engineering from the University of British Columbia in 2020. During his PhD studies, he invented and patented a novel way of producing the gelatin methacryloyl (GelMA) hydrogel, which is a versatile biomaterial used in bioprinting and pharmaceutical testing. As the founder and CEO of The GelMA Company, he is committed to making GelMA the most accessible and versatile hydrogel in the world so that more groundbreaking research can occur in the field of biotechnology.

Dr. Stephen Ryan

Dr. Stephen Ryan is a practicing physician and co-founder of PolyUnity Tech. He has explored Additive Manufacturing applications in healthcare for over 6 years as a researcher and entrepreneur. He has been involved in the creation of many 3D Printed products including medical simulations, patient-specific medical devices, PPE, and end-use hospital equipment. To make 3D Printing more accessible to hospitals, his team has built the i3D.Health portal, a digital inventory system for 3D Printable medical equipment. He believes that collaboration and strategic partnerships is the key to creating a thriving 3D printing ecosystem in healthcare.

Keith Ippel

Co-leading Spring Activator and Spring Investing Collective

Keith Ippel

With over 25 years of experience as a leader in technology & impact businesses and as an angel investor, Keith Ippel has accelerated the growth of both small and large companies and raised over $80M in angel investment and venture capital. Keith has trained more than 400 impact entrepreneurs on investment readiness and raising capital, and co-lead Spring Activator and the Spring Investing Collective

Event Moderator: 

Vidya Chamundeswari Narasimhan

Dr. Vidya Chamundeswari Narasimhan is a Process Development Manager at STEMC.ELL Technologies, where she manages a team of Associates focused on the technology transfer of new products in the liquid cell culture Media Product Portfolio! She has previously worked as a division lead scientist at New Age Meats, developing food-grade matrices and culture media for cultivated cells. Vidya obtained her Doctorate by Research from Nanyang Technological University. Her Ph.D. work focused on developing bioactive polymeric scaffolds for tissue regeneration applications. She has interned at reputed universities and institutions such as MIT-Harvard (2013) and National Chemical Laboratory, Pune India (2012). She was the title winner of the Young Persons’ World Lecture Competition, in Australia (2017), and a finalist at the Falling Walls Lab Competition in Singapore (2019). At 3DHEALS, Vidya served as the Community Manager – San Francisco from 2019 – to 2022. She has contributed to expert corner blogs and organized networking events. She is currently based in Vancouver and is working towards setting up a 3DHEALS hub on the West Coast of Canada.

3D Printing and Microfluidics

Microfluidics refers to the behavior, precise control, and manipulation of fluids that are geometrically constrained to a small scale (typically sub-millimeter) at which surface forces dominate volumetric forces…It has practical applications in the design of systems that process low volumes of fluids to achieve multiplexing, automation, and high-throughput screening.” (Wikipedia

However, most of you are already very familiar with the concept of microfluidics, often appearing as a transparent plastic chip with strategically designed channels and controlled fluid dynamics to manipulate cells or event organoids. The concept of “organ-on-a-chip” is the more popular application in the media. The infamous Theranos touted it as its central technology, which is still considered a myth by experts (we will see). However, many biotechnology companies are now employing microfluidics at scale, and its ecosystem is maturing rapidly.  Lately, 3D printing has been both a manufacturing method and an application for microfluidics. Better microfabrication techniques, new biomaterials, and expanded design capabilities add acceleration to its latest growth.

Speakers:

Jan Pal-Goetzen

Jan Pal-Goetzen is the Founder and CEO of 3D printed microTEC ,Bethesda Maryland. The company takes 3D printing beyond rapid prototyping. While pushing the resolution limits down to 1μm lateral, the unique batch approach allows mass volume production on a single 3D-printer. The solutions are always innovative and often groundbreaking in the field. Jan has been in the field of 3D printed microfluidics and packaging of microelectronics for over 10 years. He holds a PhD in Physics from Marburg University Germany.

Paul Marshall

An experienced Chartered Mechanical Engineer, Paul is an engineering consultant specialising in Life Sciences, and co-founder and CEO of Rapid Fluidics. His work focuses on the design and rapid-prototyping of microfluidic systems but also covers a wide range of other projects from medical device design through to technical reviews of water, sanitation and health projects for the Bill and Melinda Gates Foundation.

Cory Lambertson

Cory Lambertson has over 8 years of experience in additive manufacturing. He started his career in the Dental Laboratory Industry after college by joining his Father at Heartland Dental Laboratory in 2013. From there, Cory ventured off into corporate dentistry which is where he was first introduced to the Asiga brand of 3D Printers. Cory found a passion for the Asiga brand of 3D Printers due to the revolutionary changes that they bring to the dental industry. Today, Cory is the General Manager of Americas at Asiga, and is based out of Ann Arbor Michigan.

Gavin Jeffries

Gavin D. M. Jeffries is a Founder and Chief Technology Officer at Fluicell AB. Gavin holds a PhD in Chemistry from the University of Washington and is a former assistant Professor at Chalmers University of Technology. Gavin has published over 40 peer-reviewed publications with a cumulative citation count of over three thousand. As an entrepreneur/founder of two biotech and optics companies and inventor of multiple patents and technologies, Gavin has a strong background in microfluidics, single-cell analysis, and optical platform integration. Fluicell AB is a Life-Science tool company with a commercialized product portfolio of microfluidic products to investigate individual cells, primarily in the fields of drug development and regenerative medicine. Fluicell recently developed a unique high-resolution technology for bioprinting in both 2D and 3D under the name Biopixlar®. Built upon Fluicell’s patented microfluidic technology, Biopixlar can generate detailed, multi-cellular biological tissues, directly in cell culture media, without the use of a bioink. This all-in-one discovery platform helps researchers around the globe to build biological tissues for drug development, disease understanding and regenerative medicine research.

Yang Xu

Yang Xu is a postdoctoral researcher at the Center for Advanced Manufacturing, University of Southern California. He earned an M.S. degree in Computer Science and a Ph.D. degree from USC in 2021. His research interests are novel 3D printing processes for polymers, polymer-based composites, and related applications. His recent work, “In-situ Transfer Vat Photopolymerization for Transparent Microfluidic Device Fabrication”, solved the z-resolution challenge of 3D printing microfluidic devices.

Moderator:

Dr. Jenny Chen

jenny chen

Dr. Jenny Chen is trained as a neuroradiologist, founder/CEO of 3DHEALS. Her main interests include next generation education, 3D printing in the healthcare sector, automated biology, artificial intelligence. She is an angel investor who invests in Pitch3D companies.

Fundraising, Venture Capitalists, Angel Investors in Healthcare 3D Printing

One of the most exciting missions at 3DHEALS is discovering early-stage startups, meeting the founders, and helping these companies with fundraising through our Pitch3D program. Our goal is to save the founders and selected institutional investors time to meet each other at the right time along the company’s journey at zero cost to either side. Since April 20th, 2018, 3DHEALS has hosted numerous online and offline Pitch3D sessions regularly, introducing 30+ startups from all over the world to institutional investors who are interested in healthcare 3D printing, bioprinting, and adjacent fields including AI and cybersecurity (within 3D printing), 3D scanning, VR/AR, 3D Visualization, synthetic materials, and regenerative medicine. In this unique 3DHEALS virtual event, we would like you to meet some of the VCs and angel investors behind the scene and learn more about the medical device and biotechnology investment environment under the current macroeconomy. The format of this event will focus on a moderated panel discussion focusing on the current status, short-term, and longer-term outlook of the institutional investment landscape. The audience is welcome to bring many questions to this rare and unique opportunity and engage live.

Speakers:

Tak Cheung

Tak joined NEA in 2018 and is currently a Partner on the healthcare team. He focuses on medical device investments.

Prior to NEA, Tak was a Venture Partner at Merieux Development Venture Fund where he led all phases of investment for healthcare startups, including sourcing, diligence and investment approvals. Tak also co-founded Lexington Medical, a commercial-stage medical device startup in the gastrointestinal surgery space. Prior to Merieux and Lexington, Tak was VP of Business Development for the Global Surgical Division at Bausch & Lomb, and was responsible for all business development efforts in the ophthalmic surgical division. Tak has held various corporate and business development leadership roles at Edwards Lifesciences in the Heart Valve Therapy Division and Advanced Medical Optics (acquired by Johnson & Johnson).

Tak received a BS with Honors in Engineering and Applied Science from the California Institute of Technology, an MD from the University of California, Irvine, and an MBA from Harvard Business School.

Tom Gwinn

Tom Gwinn is an Investment Manager at Evonik Venture Capital (EVC) based in Silicon Valley. Tom has been actively involved in the technology community in the valley for over a decade. Prior to joining Evonik, Tom has held roles in venture capital investing, startup patent strategy, and applied physics research — providing a broad set of experiences to draw upon in support of Evonik’s investments. Tom has a B.S. in Electrical Engineering from Caltech, an M.S. in Electrical Engineering from Stanford, and a J.D. from Stanford Law School.

Tom Vogelsong

Tom is an angel investor in MedTech and a Life Science Advisor to and Director of Deal Flow for Kyto Technology and Life Science (www.kytotech.com). Tom is also an advisor to Medtech Innovator, Silicon Valley Advantage, US Angels, Edge AI and Embedded Vision Alliance, Camdo, InQCel, and Lehigh University’s new College of Health. He received his PhD in Electrical Engineering and has a background in technology, entrepreneurship, medical devices, and biochemistry. Tom scouts early-stage investment opportunities for Kyto in MedTech, BioTech, Diagnostics, and Tech. He has executive experience along with technical expertise and business development background with startups, including as CEO of venture-backed Photon Vision Systems, as well as with medium and large size companies including GE Medical. Tom has invested in startups and helped companies raise capital as well as coaching them to set a vision for growth and making connections for them to achieve success. Tom invests in MedTech and Tech directly as an angel investor and as part of Kyto.

Natalie Levy

Natalie Levy is the Founder of She’s Independent, a women-first investment group offering an entirely new way to support women’s financial independence and influence through investing and board placements. As a member-led investment group, She’s Independent marries empowerment and action, with the ultimate mission of closing the power gap in investing by getting more women on the cap table, in the boardroom, and into positions of influence. Over the next 12 months, She’s Independent plans to deploy $1.5M of capital collectively, and has invested in 9 deals since its formation in January 2022. An accomplished engineer turned Wall Street derivatives trader, investor, and advisor, Natalie has over a decade of tech operational experience, a portfolio of 30+ seed through later stage private investments, and has experienced liquidity events across 3 of the first 4 investments in her growth technology portfolio with an average return >20X. Natalie resides in Boulder, CO with her loving rescue pup Beans and is passionate about gender equity and mental health awareness.

Jimmy Lu

Jimmy is a Co-Founder & Managing Director of Eos BioInnovation, a new venture that incubates projects and invests in early-stage startups in the Regenerative Medicine field originating from top academic and research institutions.  

Prior to Eos, Jimmy was a Managing Director/Senior Partner in the San Francisco office of WI Harper, bringing over 25+ years of technology/healthcare and venture capital experience. While at WI Harper, he had been the leader of the healthcare team investing in the medical device, healthcare services and biotech/life science sectors. Jimmy was a Board Director of DeepBiome Therapeutics, Panorama Medicine, Kindstar Globalgene Technology, China Diagnostics Medical Corporation (Chemclin), StemCyte Inc., and Circle Pharma.

Before joining WI Harper, Jimmy co-founded and was a General Partner of iD Ventures (Acer Technology Ventures), with key investments that included iRobot Corporation, Harmonix Music, Monolithic Power Systems, and Fortinet.

Jimmy earned a BA from Yale College, an MBA from Harvard Business School and a JD from UC Berkeley School of Law. He serves on the University of Florida College of Engineering West Coast Advisory Board, and he is a member of the advisory board of Elm Street Ventures and is Co-Chair of the Investment Committee for the National Foundation for Cancer Research AIM-HI Accelerator Fund (Women’s Venture Competition).

Arno Held

Arno Held is Managing Partner of AM Ventures and specializes on the firm‘s ecosystem, as well as its global footprint and organizational growth. He started AM Ventures together with Johann Oberhofer in 2014. In total, Arno has more than 23 years of experience in industrial laser and manufacturing technologies and spent more than half of this time in the world of industrial 3D printing. 

Since founding AM Ventures, Arno has been instrumental in building the AM Ventures team that has scouted more than 2,500 3D printing startups all over the world, conducted more than 35 rounds, built a €100m VC fund and today holds a portfolio of 17+ shareholdings in 6 countries on 3 continents. 

Arno holds a diploma degree in industrial engineering and management from the University of Applied Sciences Karlsruhe (Germany) as well as an international executive MBA from the University of St. Gallen (Switzerland). Arno completed his studies in Shanghai, China and Cape Town, South Africa.

Moderator:

Dr. Jenny Chen

jenny chen

Dr. Jenny Chen is trained as a neuroradiologist, and founder/CEO of 3DHEALS. Her main interests include next-generation education, 3D printing in the healthcare sector, automated biology, and artificial intelligence. She is an angel investor who invests in Pitch3D companies.

Point of Care 3D Printing

Point of care 3D printing is becoming one of the biggest attractions in adopting 3D printing in healthcare systems because it demonstrates the ability to decentralize manufacturing personalized medical devices. The medical devices can range from anatomical modeling, and implants, to surgical guides based on the latest updates from all over the world. However, for companies interested in expanding markets either locally or regionally, understanding the complex relationships among different players and regulations are critical.

At the end of 2021, the FDA published its discussion paper on the subject, inviting the public to submit comments so that more clarifying regulatory guidance can be created.

Speaker:

Ido Bitan

Ido Bitan is a Product Manager in Stratasys’s Medical Solutions Department. Mr. Bitan received a Bachelor of Science in biomedical engineering from Beer Sheva University in Israel. Mr. Bitan began his career at a start-up company, where he worked as part of the Research & Development team to develop new cancer-detecting equipment that assists surgeons in the operating room. Mr. Bitan has helped establish Stratasys’s adaption to the medical industry, leading the development of the Digital Anatomy Printer, Digital Anatomy Creator, and many more of the accompanying materials and software features. The Medical Department at Stratasys continues to push the boundaries of technology to improve patient care worldwide, and Mr. Bitan is passionate about improving the healthcare system to ensure better outcomes for any patient.

Martin Herzmann

Martin Herzmann started his medtech career in 1999 at Brainlab Headquarter in Germany. After wworking positions in Sales, Product Management and Business Development, he joined Ziehm Imaging in 2007 and worked for another eight years as Marketing Director for medical capital equipment. In 2015, he joined the Materialise and transformed his past experiences into medical 3D printing. In 2019, Martin joined Kumovis as Business Development Manager. The company enables medical device companies and hospitals to manufacture 3D printed implants, instruments and guides following regulatory standards and norms. Kumovis has a clear focus on medical 3D printing with high-performance polymers and biodegradable polymers. With the merger of Kumovis and 3D Systems in April 2022 Martin now can focus even more on additive manufacturing at Point-of-Care and accelerates the global implementation of clinical applications such as cranial implants printed in PEEK.

Kerim Genc

Kerim Genc

Kerim Genc is the Business Development Manager for the Simpleware Product Group at Synopsys. He joined Simpleware in 2011 as a Technical Sales Consultant and is currently responsible for managing global sales, business development and partnerships. He received his BS and MS in biomechanics from the University of Calgary and the Pennsylvania State University respectively and completed his PhD in Biomedical Engineering at Case Western Reserve University looking at countermeasures to spaceflight induced bone loss and fracture risk.

Silvina Zabala-Travers

Silvina Zabala-Travers

– MD and Radiologist Degree from Universidad de la República (UdelaR) in Uruguay – 3D training at Sant Joan de Déu Hospital 3D Lab (Expert3D and internship) in Barcelona, Spain Dr Zabala-Travers introduced 3D technologies to the academic medical field in Uruguay in 2019 and has since pioneered its development with particular interest in training radiologists to be part of the workflow to ensure process precision. She founded and leads the Surgical Virtual Planning and 3D Printing Area at the Radiology Department Pereira Rossell Hospital Center, a state and university laboratory for the application of 3D technologies in diagnostics, surgical virtual planning, clinical simulation and education for pediatric and adult patients. She recently teamed-up with a custom-implant manufacturer to co-found UPGRADE Medicals, a healthcare 3D-technology start-up which provides anatomical biomodels, virtual planning with surgical guide design and custom implant in metal, PEEK and bioabsorbable materials. She is invited professor at the Expert3D course and has given many conferences sharing her experience implementing a hospital 3D lab in a low-resource facility, as well as hands-on training on segmentation, biomodeling and virtual planning for bioengineers and surgical specialists.  She presides the Latin American Society of Pediatric Radiology (SLARP) New Technologies Committee, a network for the implementation of 3D technologies in Latin American countries. She also works as Radiology Section Editor for the Elsevier Journal Annals of 3D Printed Medicine, currently Guest Editor for the Special Issue “Virtual Planning and Personalized Medicine”.

Moderator:

Dr. Jenny Chen

jenny chen

Dr. Jenny Chen is trained as a neuroradiologist, founder/CEO of 3DHEALS. Her main interests include next generation education, 3D printing in the healthcare sector, automated biology, artificial intelligence. She is an angel investor who invests in Pitch3D companies.

3D Printing for O&P, Assistive Devices

The field of 3D printed orthotics and prosthetics has advanced significantly since the days of ENABLE hands. These advancements include not just hardware, and materials, but also software, designs, 3D scanning, and lately completely digitalized workflow at the point of care, often leveraging machine learning and artificial intelligence. More importantly, technologists are now working more closely with clinicians to create a more efficient and more evidence-based patient-centered clinical solution. Join a group of entrepreneurs next Thursday and explore the latest update, challenges, and solutions to 3D printed orthotics, prostheses, and assistive devices. 

Speakers:

Diana Hall

Diana Hall graduated from Colorado School of Mines in 1997 with a degree in Chemical Engineering, and has worked in process engineering and software for Fortune 500 companies across the country. She completed her MBA at Colorado State University in Fort Collins in 2007, worked as a Business Development Director for nonprofits, and founded a mentoring program for children in poverty. Diana holds patents on 3D-printed exoskeletons, and founded ActivArmorTM in 2014. Diana has established partnerships with professional athletes, medical specialists, research hospitals and business leaders to develop custom medical and sports products. Diana was named Colorado Manufacturing Woman of the Year in 2022, and has won many business awards including the Small Business of the Year award, the Southern Colorado Entrepreneurship Competition’s Social Entrepreneurship award, the regional InnovateHER competition, Nationwide Insurance’s national $100,000 Pitch To Win competition, and is listed as Top 100 Colorado Manufacturers. She has spoken at several venues on the topic of 3D design and printing, small business ownership and start-ups, economic development and entrepreneurship, and has given a TEDx talk on the future of mass customization in design and manufacturing in 2015.

ActivArmorTM is now a global biomedical company, with 5 international contracts and more than $2.2M in investment. It is the first Pueblo company to be awarded the Colorado Office of Economic Development’s Advanced Industries Grant, bringing more than $250,000 in state funding to Pueblo for primary job creation in the areas of bio-science and advanced manufacturing. ActivArmorTM casts are being worn by professional athletes, including NFL players, and holds contracts with leading orthopedic clinics across the country, including Jacksonville Orthopedic Institute (the official sports medicine provider for the Jaguars, Sharks, Blue Wave and Armada), St. Lukes Hospital Network, and Children’s Hospital Colorado. ActivArmor is now available in 10 countries. A full list can be found on their website at www.ActivArmor.com.

Read Diana’s interview with us: https://3dheals.com/interview-with-diana-hall-activearmor-tm/

Florian De Boeck

Florian De Boeck is a serial entrepreneur who has always felt the urge to build and create. He has a master’s degree in biomedical engineering from the Politecnico di Milano, in Italy. At the age of 21, he started working for Engineer Without Borders in Madagascar, Congo, and Burundi. The objective was to help hospitals improve their waste management. After this first professional experience, Florian decided to set out to apply 3D printing technology to orthopedics. Florian is the co-founder of Spentys, a medical platform enabling healthcare providers to create patient-specific orthoses and prostheses cheaper and faster, thanks to 3D technologies. Today, Spentys has around 30 employees, has raised VC money, and is quickly growing. The solution is now available in more than 20 countries around the world and is used on a daily basis by more than 100 medical professionals. Florian has also launched a coworking space in Brussels (SanoHub, meaning the Healthy Hub) and has re-started the Family Brewery with his brothers and sister (De Boeck Family Brewery). Florian is still active and traveling for Engineer Without Borders during his free time.

Read Florian’s interview with us: https://3dheals.com/interview-with-florian-de-boeck-spentys/

Jacopo Lazzaro

Architect since 2012. Startups founder with focus on 3D scanning and 3D data interpretation and design. He has been freelance designer, web designer and graphic designer. Teacher of 3D modeling, 3D making and occasional developer. In 2014 he designed his first 3D printed cast and patented several ideas related to the 3D world among which PlayCast instantaneous 3D scanner. Today CEO and technical director and proud father of two little girls (and a cat).

Read Jacopo’s interview with us: https://3dheals.com/interview-with-jacopo-lazzaro-playcast/

Alexander Geht

Alexander is an experienced industrial designer with a background in practical electronics engineering. Alexander worked in the military, health care, design, and manufacturing fields with an Interest in human-centered design, research, and development(R&D), emphasis on assistive technology. Last ten years Alexander focuses on Digital and Additive Manufacturing (AM), and focuses on the design of adaptive products, creating innovative and affordable products. Alexander is a founder of ‘testa-seat’ which simplify complex manufacturing process to make seating systems affordable.

Moderator: 

Dr. Jenny Chen

jenny chen

Dr. Jenny Chen is trained as a neuroradiologist, founder/CEO of 3DHEALS. Her main interests include next generation education, 3D printing in the healthcare sector, automated biology, artificial intelligence. She is an angel investor who invests in Pitch3D companies.

Post Processing for Healthcare 3D Printing

One of the biggest challenges in 3D printing adaption, in healthcare or not, is that a 3D-printed object is often not ready to be used immediately after production. This often unspoken reality among additive manufacturing evangelists is drawing more attention as the technology recruits more new users, who are often shocked and frustrated with the real cost of adoption. In this webinar, we invite world-class industry veterans to detail the challenges as well as solutions specific to an audience interested in using 3D printing in healthcare and life sciences.

Speakers: 

Craig Rosenblum

Craig Rosenblum is the Vice President & General Manager of Himed. Over 30 years of operation, Himed has become a global leader in calcium phosphate-based biomaterial production and has developed proprietary plasma spray coatings and surface treatments. Craig and his team collaborate directly with dental and medical device manufacturers around the world to provide innovative biomaterial solutions. Craig discovered a unique application for MATRIX MCD® post-processing additively manufactured titanium implantable devices using Himed’s proprietary and biocompatible resorbable blast media. Craig received his B.S. and M.S. degree in Materials Science & Engineering with a Biomaterials concentration from Johns Hopkins University. With a focus in biomaterials characterization, his groundbreaking research explored the variations in the microstructure and mechanical properties of dental enamel. These studies were the first to demonstrate the unique heterogeneous nature of enamel. Craig currently serves on The Johns Hopkins University Materials Science & Engineering Advisory Board.

Interview with Craig Rosenblum: 3D Printing Post Processing

Lluis Gil-Vernet Mas

Chief Customer Officer at GPAINNOVA

•BA in Aerospace Vehicle Engineering from the Polytechnic
University of Catalonia (ESEIAAT School)
•Master in Advanced Science and Technology of Materials
from the Polytechnic University of Catalonia (EEBE School)
•Student of Business Administration and Management at the Open
University of Catalonia (UOC)
As an aeronautical engineer specializing in material science and business management, Laia based her experience in a startup in the industrial sector. She managed to develop herself in various professional fields, carrying out highly demanding and committed challenges that have helped the growth and stabilization of the company.

Laia Fontelles

Chief Customer Service at GPAINNOVA

BA in Aerospace Vehicle Engineering from the Polytechnic
University of Catalonia (ESEIAAT School)

Master in Advanced Science and Technology of Materials
from the Polytechnic University of Catalonia (EEBE School)

Student of Business Administration and Management at the Open
University of Catalonia (UOC)

As an aeronautical engineer specializing in material science and business management, Laia based her experience in a startup in the industrial sector. She managed to develop herself in various professional fields, carrying out highly demanding and committed challenges that have helped the growth and stabilization of the company.

Snehashis Pal

Snehashis is a researcher at the University of Maribor in Slovenia. He is also founder and Managing Director of GAFI, an Indian educational hub that encourages young researchers to pursue cutting-edge research. He is president of the 8th International Conference on Additive Technologies (iCAT 2023), which will be held in Maribor, Slovenia. He has eight years of research experience in additive manufacturing of metals and tailoring their properties for biomedical applications, having collaborated with India, Slovenia, Slovakia, Kosovo, Portugal and the United Kingdom. During his PhD studies, he was awarded the “Best Young Scientist Award” and “The Best Paper” at different international conferences.

Speaker/Moderator: 

Dr. Pásztor Zsolt

Zsolt Pásztor

Zsolt is Co-founder and Managing Director of PREMET, a Hungarian MedTech company focusing on the production of medical devices, including patient specific implants, by additive manufacturing. The company puts a high emphasis on the continuous development of all elements of the production workflow – titanium 3D printing, thermal and surface treatment – and has been involved in several international R&D projects. Zsolt plays an important role in the management of the developments, and focuses especially on the improvement of the printing procedure and the different type of surface treatments. He is a Community Manager at 3DHEALS, co-founder and Vice-President of the Hungarian Additive Technology Association, and Leader of the “3D Printing in the Health Sector” working group of MediKlaszter, an accredited MedTech cluster. He was the Lead Expert of a recent Transnational Cooperation Project, aiming at collecting and disseminating best practices in the field of 3D Printing in the Health Sector in Central Europe.

From Esthetic to Functionality – Perspectives of Anodized 3D Printed Titanium Dental Restorations

Moderator: 

Dr. Jenny Chen

jenny chen

Dr. Jenny Chen is trained as a neuroradiologist, and founder/CEO of 3DHEALS. Her main interests include next-generation education, 3D printing in the healthcare sector, automated biology, and artificial intelligence. She is an angel investor who invests in Pitch3D companies.

The Ultimate Resource Center for Healthcare 3D Printing (7/28/22 Version)